Over the last 10 years, ALKEM has outperformed most of the Indian pharma companies in the domestic market, driven by its consistent launches in acute therapies like anti-infective, pain/analgesic and vitamins, while also growing its presence in high-growth chronic therapies like CNS, cardiac, derma and antidiabetic.
Globally, ALKEM has launched 20 products in the US market and has 50+ pending ANDAs. On the back of improved presence in the chronic business and significant leverage from the US segment, we expect ALKEM’s earnings to grow at a 14% CAGR over the next three years. This will be supported by 12% revenue CAGR and 300bp margin expansion over FY17-20E.
Motilal Oswal was founded in 1987 as a small sub-broking unit, with just two people running the show. Today it has a 2000 member team with a networth of Rs7 bn and market capitalization as of March 31, 2008 at Rs19 bn.
For more information please write in to [email protected]
Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.